SCHEMBL3247660

SCHEMBL3247660

Cc1ccc(-c2n[nH]cc2-c2ccnc(Nc3cccc(CN4CCN(C)CC4)c3)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 5/20 0.60
JAK3 P52333 4/20 0.60
AIMP2 Q13155 1/20 0.49
ABL1 P00519 1/20 0.48
PDGFRB P09619 1/20 0.48
BCR P11274 1/20 0.48
SRC P12931 1/20 0.48
PDGFRA P16234 1/20 0.48
SYK P43405 1/20 0.48
ACVR1 Q04771 1/20 0.48
KIT P10721 2/20 0.47
ACP1 P24666 2/20 0.46
FLT3 P36888 2/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
CCNE1 P24864 1/20 0.46
CDK2 P24941 1/20 0.46
CDK7 P50613 1/20 0.46
CCNH P51946 1/20 0.46
MNAT1 P51948 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3258021 0.94 JAK2 (0.60) JAK2JAK3AIMP2ABL1PDGFRB
SCHEMBL3254455 0.94 JAK2 (0.56) JAK2JAK3AIMP2ABL1PDGFRB
SCHEMBL3249693 0.93 JAK2 (0.59) JAK2JAK3AIMP2ABL1PDGFRB
SCHEMBL3247584 0.90 JAK2 (0.58) JAK2JAK3ABL1PDGFRBBCR
SCHEMBL3279216 0.85 JAK2 (0.43) JAK2JAK3AIMP2ABL1BCR
SCHEMBL3255257 0.83 JAK2 (0.53) JAK2JAK3ACVR1CDK1CCNB1
SCHEMBL3252196 0.83 JAK2 (0.58) JAK2JAK3AIMP2RET
SCHEMBL3253533 0.82 JAK2 (0.49) JAK2JAK3ABL1BCRACVR1
SCHEMBL3254348 0.81 AIMP2 (0.49) JAK2AIMP2ABL1BCRSYK
SCHEMBL4203689 0.80 AXL (0.51) JAK2JAK3AIMP2ABL1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521749-B8 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2010-12-22 EP claimed
EP-1521749-B1 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2010-05-19 EP claimed
US-7691855-B2 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives NOVARTIS AG (CH) 2010-04-06 US claimed
US-20060106027-A1 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives FURET PASCAL 2006-05-18 US claimed
EP-1521749-A1 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES Novartis AG (CH) 2005-04-13 EP claimed
WO-2004005282-A1 PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2004-01-15 WO claimed
EP-1521749-B1 PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES NOVARTIS AG (CH) 2010-05-19 EP disclosed
US-7691855-B2 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives NOVARTIS AG (CH) 2010-04-06 US disclosed
US-20060106027-A1 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives FURET PASCAL 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106027-A1 Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives MKI67, CCNI, PAH JAK2 24/4885JAK3 41/4885AIMP2 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.